CERITINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H36ClN5O3S
Molecular Weight	558.135
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(=O)C(C)C)=N3

InChI

InChIKey=VERWOWGGCGHDQE-UHFFFAOYSA-N

InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)

HIDE SMILES / InChI

Molecular Formula	C28H36ClN5O3S
Molecular Weight	558.135
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755s000lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=2467504; https://www.novartis.ca/sites/www.novartis.ca/files/zykadia_scrip_e.pdf

Ceritinib is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). Ceritinib is approved by FDA and is indicated for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. Ceritinib also targets insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
ALK tyrosine kinase receptor 24 Target ID: CHEMBL4247 Sources: https://www.novartis.ca/sites/www.novartis.ca/files/zykadia_scrip_e.pdf	Antagonist 2849		0.15 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Non-small cell lung cancer 211 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755s000lbl.pdf	Primary		Approved 8583	ZYKADIA Approved Use ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Launch Date 2014

C_max

Value	Dose	Co-administered	Analyte	Population
800 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28740365	750 mg 1 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
917 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28729021/	450 mg 1 times / day multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
16500 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28740365	750 mg 1 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28729021/	450 mg 1 times / day multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
40 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28740365	750 mg 1 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
3% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28740365	750 mg 1 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CERITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
450 mg 1 times / day steady, oral Recommended Dose: 450 mg, 1 times / day Route: oral Route: steady Dose: 450 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	unhealthy, 37 years (range: 29–67 years) Health Status: unhealthy Age Group: 37 years (range: 29–67 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (all grades, 33%) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf
450 mg 1 times / day steady, oral Recommended Dose: 450 mg, 1 times / day Route: oral Route: steady Dose: 450 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	unhealthy, 37 years (range: 29–67 years) Health Status: unhealthy Age Group: 37 years (range: 29–67 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (all grades, 100%) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf
450 mg 1 times / day steady, oral Recommended Dose: 450 mg, 1 times / day Route: oral Route: steady Dose: 450 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125	unhealthy, 37 years (range: 29–67 years) Health Status: unhealthy Age Group: 37 years (range: 29–67 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26020125	Other AEs: Vomiting, Abdominal pain... Other AEs: Vomiting (all grades, 100%) Abdominal pain (all grades, 17%) Fatigue (all grades, 33%) Blood creatinine increased (all grades, 50%) Decreased appetite (all grades, 50%) Alanine aminotransferase increased (all grades, 33%) Aspartate aminotransferase increased (all grades, 33%) Neutropenia (all grades, 33%) Rash (all grades, 50%) Maculopapular rash (17%) Stomatitis (33%) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125
600 mg 1 times / day steady, oral Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125/	unhealthy, 39 years (range: 34–61 years) Health Status: unhealthy Age Group: 39 years (range: 34–61 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26020125/	DLT: Lipase increased... Dose limiting toxicities: Lipase increased (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125/
750 mg 1 times / day steady, oral MTD Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	unhealthy, 53 years Health Status: unhealthy Age Group: 53 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Disc. AE: Pneumonitis... Other AEs: Pneumonitis... AEs leading to discontinuation/dose reduction: Pneumonitis (grade 3-4, 3%) Other AEs: Pneumonitis (all grades, 4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf
750 mg 1 times / day steady, oral MTD Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	unhealthy, 54 years (range: 22- 81 years) Health Status: unhealthy Age Group: 54 years (range: 22- 81 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	DLT: ALT increased, AST increased... Disc. AE: Nausea, Diarrhea... Other AEs: Nausea, Diarrhea... Dose limiting toxicities: ALT increased (grade 3-4, 34%) AST increased (grade 3-4, 21%) AEs leading to discontinuation/dose reduction: Nausea (grade 3-4, 2.6%) Diarrhea (grade 3-4, 4.8%) Vomiting (grade 3-4, 5%) GGT increased (grade 3-4, 49%) Creatinine increased (grade 3-4, 4.2%) Amylase increased (grade 3-4, 8%) Lipase increased (grade 3-4, 6%) Other AEs: Nausea (all grades, 69%) Diarrhea (all grades, 85%) Vomiting (all grades, 67%) Abdominal pain (all grades, 40%) Abdominal pain upper (all grades, 40%) Abdominal discomfort (all grades, 40%) Epigastric discomfort (all grades, 40%) Abdominal pain (grade 3-4, 3.7%) Abdominal pain upper (grade 3-4, 3.7%) Abdominal discomfort (grade 3-4, 3.7%) Epigastric discomfort (grade 3-4, 3.7%) Constipation (all grades, 20%) Dyspepsia (all grades, 15%) Gastroesophageal reflux disease (all grades, 15%) Dysphagia (all grades, 15%) Dyspepsia (grade 3-4, 0.5%) Gastroesophageal reflux disease (grade 3-4, 0.5%) Dysphagia (grade 3-4, 0.5%) Fatigue (all grades, 45%) Asthenia (all grades, 45%) Fatigue (grade 3-4, 7%) Asthenia (grade 3-4, 7%) Non-cardiac chest pain (all grades, 21%) Non-cardiac chest pain (grade 3-4, 1.1%) Back pain (all grades, 19%) Back pain (grade 3-4, 1.6%) Pyrexia (all grades, 19%) Pain in extremity (all grades, 13%) Musculoskeletal pain (all grades, 11%) Musculoskeletal pain (grade 3-4, 0.5%) Pruritus (all grades, 11%) Pruritus (grade 3-4, 0.5%) Decreased appetite (all grades, 34%) Decreased appetite (grade 3-4, 1.1%) Weight loss (all grades, 24%) Weight loss (grade 3-4, 3.7%) Rash (all grades, 21%) Dermatitis acneiform (all grades, 21%) Rash maculo-papular (all grades, 21%) Rash (grade 3-4, 1.1%) Dermatitis acneiform (grade 3-4, 1.1%) Rash maculo-papular (grade 3-4, 1.1%) Headache (all grades, 19%) Headache (all grades, 0.5%) Dizziness (grade 3-4, 12%) Dizziness (grade 3-4, 1.1%) QT interval prolonged (all grades, 12%) QT interval prolonged (grade 3-4, 2.6%) Pericardial effusion (all grades, 4.2%) Pericarditis (all grades, 4.2%) Pericardial effusion (grade 3-4, 1.6%) Pericarditis (grade 3-4, 1.6%) Cough (all grades, 25%) Pneumonia (serious, 4%) Pleural effusion (serious, 4%) ALT increased (all grades, 91%) AST increased (all grades, 86%) GGT increased (all grades, 84%) Alkaline phosphatase increased (all grades, 81%) Alkaline phosphatase increased (grade 3-4, 12%) Creatinine increased (all grades, 77%) Hyperglycemia (all grades, 53%) Hyperglycemia (grade 3-4, 10%) Hypophosphatemia (all grades, 38%) Hypophosphatemia (grade 3-4, 3.7%) Amylase increased (all grades, 37%) Hyperbilirubinemia (all grades, 15%) Hyperbilirubinemia (grade 3-4, 0.5%) Lipase increased (all grades, 13%) Anemia (all grades, 67%) Anemia (grade 3-4, 4.2%) Neutropenia (all grades, 27%) Neutropenia (grade 3-4, 2.1%) Thrombocytopenia (all grades, 16%) Thrombocytopenia (grade 3-4, 1%) Vision decreased (4%) Blurred vision (4%) Photopsia (4%) Accommodation disorder (4%) Presbyopia (4%) Visual acuity reduced (4%) Vitreous floaters (4%) Bradycardia (4%) Hepatotoxicity (2%) Renal failure (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26020125 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438 inducer 440	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP2B6 926 CYP2C19 2057 CYP2E1 1060 P-gp 1741 BCRP 910 OATP1B1 1079 OATP1B3 961 OAT1 725 OAT3 747 OCT2 779 OCT1 620	CYP3A 220 P-gp 2052 BCRP 697 OCT1 393 OAT2 125 OATP1B1 503 OATP2B1 122	CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	no
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 0.2 uM]
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 2 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 2 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 20 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 30 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 5 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=44 Page: -	yes [IC50 70 uM]
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes [Inhibition 5 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes [Inhibition 5 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes [Inhibition 5 uM]
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes [Inhibition 5 uM]
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=46 Page: -	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A 220	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=20 Page: -	major	yes (co-administration study) Comment: Ceritinib is primarily metabolized by CYP3A, and is also a reversible and time-dependent inhibitor of CYP3A in vitro. Coadministration of ketoconazole (a strong CYP3A inhibitor) 200 mg twice daily for 14 days and a single dose of 450 mg ceritinib increased ceritinib AUC by 2.9- fold and Cmax by 20% in healthy subjects. Coadministration of rifampin (a strong CYP3A inducer) 600 mg daily for 14 days and a single dose of 750 mg ceritinib decreased ceritinib AUC by 70% and Cmax by 44% in healthy subjects. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=20 Page: -
OAT2 125	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	no
OATP2B1 122	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	no
OCT1 393	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=37 Page: -	yes
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -	yes	no (co-administration study) Comment: Ko143 (a BCRP inhibitor) had a smaller effect on the reduction of efflux ratio to 121 at 3 μM ceritinib, indicating that an in vivo DDI study with a BCRP inhibitor is not necessary. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf#page=49 Page: -

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000PharmR.pdf#page=27 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:78432	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:78432
ChemicalBook	CB82652832	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB82652832
MolPort	MolPort-035-395-774	https://www.molport.com/shop/molecule-link/MolPort-035-395-774
Selleck Chemicals	ldk378	http://www.selleckchem.com/products/ldk378.html
ZINC	ZINC000096272772	http://zinc15.docking.org/substances/ZINC000096272772

PubMed

Title	Date	PubMed
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.	2015-07	26020125
The EML4-ALK oncogene: targeting an essential growth driver in human cancer.	2015	25971657
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.	2014-06	24675041
Overcoming drug resistance in ALK-rearranged lung cancer.	2014-03-27	24670172
Ceritinib in ALK-rearranged non-small-cell lung cancer.	2014-03-27	24670165
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.	2013-07-25	23742252
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.	2007-01-02	17185414

Patents

Sample Use Guides

In Vivo Use Guide

750 mg orally once daily. Administer ZYKADIA on an empty stomach (i.e., do not administer within 2 hours of a meal).

Route of Administration: Oral

In Vitro Use Guide

In vitro Ceritinib inhibited ALK+-NSCLC cell lines (H3112 and H2228) with GIC50 values of 6.3 and 3.8 nM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:52:03 GMT 2025` Edited by `admin` on `Mon Mar 31 22:52:03 GMT 2025`
Record UNII	K418KG2GET
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ceritinib [INN]

Preferred Name

English

CERITINIB

Official Name

English

CERITINIB [MI]

Common Name

English

2,4-PYRIMIDINEDIAMINE, 5-CHLORO-N4-(2-((1-METHYLETHYL)SULFONYL)PHENYL)-N2-(5-METHYL-2-(1-METHYLETHOXY)-4-(4-PIPERIDINYL)PHENYL)-

Systematic Name

English

CERITINIB [ORANGE BOOK]

Common Name

English

CERITINIB [USAN]

Common Name

English

NVP-LDK-378-NX

Code

English

LDK-378

Code

English

5-CHLORO-N4-(2-((1-METHYLETHYL)SULFONYL)PHENYL)-N2-(5-METHYL-2-(1-METHYLETHOXY)-4- (PIPERIDIN-4-YL)PHENYL)PYRIMIDINE-2,4-DIAMINE

Systematic Name

English

ZYKADIA

Brand Name

English

LDK378

Code

English

5-CHLORO-N2-(5-METHYL-4-(PIPERIDIN-4-YL)-2-(PROPAN-2-YLOXY)PHENYL)-N4-(2-(PROPANE-2- SULFONYL)PHENYL)PYRIMIDINE-2,4-DIAMINE

Systematic Name

English

NVP-LDK378-NX

Code

English

CERITINIB [JAN]

Common Name

English

CERITINIB [VANDF]

Common Name

English

Ceritinib [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C141136